Last reviewed 2026-04-22 · How we verify

FosD

FosD is a phosphodiesterase 3 (PDE3) inhibitor that increases intracellular cAMP levels to promote vasodilation and improve cardiac contractility.

FosD is a phosphodiesterase 3 (PDE3) inhibitor that increases intracellular cAMP levels to promote vasodilation and improve cardiac contractility. Used for Acute decompensated heart failure, Cardiogenic shock.

At a glance

Mechanism of action

By inhibiting phosphodiesterase 3, FosD prevents the breakdown of cyclic adenosine monophosphate (cAMP), leading to increased cAMP concentrations in vascular smooth muscle and cardiac tissue. This results in vasodilation, reduced peripheral vascular resistance, and positive inotropic effects, improving hemodynamics in heart failure and cardiogenic shock.

Approved indications

• Acute decompensated heart failure
• Cardiogenic shock

Common side effects

• Hypotension
• Tachycardia
• Arrhythmias
• Headache

Key clinical trials

• A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects (PHASE1)
• A Single and Multiple Dose Study to Assess Blood and Urine Drug Levels of Fostamatinib in Healthy Japanese Subjects (PHASE1)
• Evaluation of the Drug-drug Interaction Between FosD and Verapamil When Taken Together in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• FosD CI brief — competitive landscape report
• FosD updates RSS · CI watch RSS
• AstraZeneca portfolio CI